Celyad Oncology S.A.
CYAD · NASDAQ
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $19 | $11 | $12 | $10 |
| - Cash | $0 | $6 | $7 | $5 |
| + Debt | $0 | $1 | $1 | $1 |
| Enterprise Value | $19 | $6 | $6 | $5 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1,128.6% | -75.9% | 31.8% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 98.3% | 35.7% | 56.9% | -902.3% |
| EBITDA | -$3 | -$3 | -$4 | -$4 |
| % Margin | -1,646.5% | -19,921.4% | -7,703.4% | -10,040.9% |
| Net Income | -$3 | -$3 | -$5 | -$4 |
| % Margin | -1,616.3% | -21,742.9% | -8,117.2% | -8,500% |
| EPS Diluted | -0.067 | -0.12 | -0.16 | -0.17 |
| % Growth | 44.1% | 25% | 5.9% | – |
| Operating Cash Flow | – | -$3 | -$7 | -$8 |
| Capital Expenditures | – | $0 | -$1 | -$0 |
| Free Cash Flow | – | -$3 | -$7 | -$9 |